
## **Emily Boozalis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4422019/publications.pdf Version: 2024-02-01



EMILY ROOZALIS

#	Article	IF	CITATIONS
1	Ethnic differences and comorbidities of 909 prurigo nodularis patients. Journal of the American Academy of Dermatology, 2018, 79, 714-719.e3.	0.6	105
2	Clinical characteristics and disease burden in prurigo nodularis. Clinical and Experimental Dermatology, 2021, 46, 1277-1284.	0.6	22
3	Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. Journal of the American Academy of Dermatology, 2019, 80, 1449-1451.	0.6	21
4	Allergen of the Year alkyl glucoside is an ingredient in top-selling sunscreens and facial moisturizers. Journal of the American Academy of Dermatology, 2018, 78, 809-810.	0.6	19
5	Mirtazapine for the Treatment of Chronic Pruritus. Medicines (Basel, Switzerland), 2019, 6, 73.	0.7	19
6	Pruritus in Black Skin: Unique Molecular Characteristics and Clinical Features. Journal of the National Medical Association, 2021, 113, 30-38.	0.6	16
7	Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic. Journal of the American Academy of Dermatology, 2020, 83, 1529-1533.	0.6	15
8	ltching at night: A review on reducing nocturnal pruritus in children. Pediatric Dermatology, 2018, 35, 560-565.	0.5	14
9	Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus. Journal of the American Academy of Dermatology, 2018, 78, 192-194.	0.6	13
10	Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti― <scp>CD</scp> 20 monoclonal antibodies. British Journal of Dermatology, 2019, 180, 1238-1239.	1.4	12
11	Demographic characteristics of teenage boys with horizontal striae distensae of the lower back. Pediatric Dermatology, 2018, 35, 59-63.	0.5	11
12	Selective serotonin reuptake inhibitors for the treatment of chronic pruritus. Journal of Dermatological Treatment, 2018, 29, 812-814.	1.1	10
13	Tricyclic antidepressants for the treatment of chronic pruritus. Journal of Dermatological Treatment, 2021, 32, 124-126.	1.1	8
14	Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non–Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 261.	3.4	5
15	Effects of neuroimmune axis modulation by aprepitant on antipruritic and global disease severity in patients with cutaneous T-cell lymphoma. British Journal of Dermatology, 2018, 178, 1221-1222.	1.4	4
16	Food and drug administration approval process for dermatology drugs in the United States. Journal of Dermatological Treatment, 2018, 29, 536-538.	1.1	3
17	Clinical utility of marketing terms used for over-the-counter dermatologic products. Journal of Dermatological Treatment, 2018, 29, 841-845.	1.1	2
18	Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. Medicines (Basel, Switzerland), 2019, 6, 114.	0.7	2

#	Article	IF	CITATIONS
19	Oesophageal epidermal naevi as a feature of systematised epidermal naevus syndrome. Australasian Journal of Dermatology, 2018, 59, 128-130.	0.4	1